TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02958696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0018318
Description: Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0018318
Description: Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0018318
Description: Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
Study: NCT00613886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmable Shunt Insertion (Codman, Medtronic)
Description: Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessments in physical therapy, occupational therapy, and speech therapy
Description: Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
Study: NCT03183258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sentinel skin flap
Description: Donor-derived vascularised composite allograft (sentinel skin flap)
Study: NCT03990415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
Study: NCT02110537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Acupuncture
Description: Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flecainide
Description: Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: flecainide
Description: Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
Study: NCT04679922

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Enhancement around dental implant
Description: Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Enhancement around dental implant
Description: Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
Study: NCT00705250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hcl
Description: Patients will receive bendamustine 120mg/m\^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is \> 1000/ul and the platelet count is \> 75,000/ul.
Study: NCT00774644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Study: NCT02931968

Intervention type: DEVICE
Intervention: Monolithic zirconia prosthesis
Description: Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
Study: NCT00948129

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01438034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: 0.24 nmol/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: 75 ng/kg
Study: NCT04316936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omidria
Description: phenylephrine 1% and ketorolac 0.3% intraocular solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omidria
Description: phenylephrine 1% and ketorolac 0.3% intraocular solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omidria
Description: phenylephrine 1% and ketorolac 0.3% intraocular solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza (dexamethasone ophthalmic insert) 0.4mg
Description: intracanalicular dexamethasone insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexycu, 9% Intraocular Suspension
Description: dexamethasone intraocular suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1%
Description: standard postoperative ophthalmic drop regimen
Study: NCT02182479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® via Respimat®, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® via Respimat®, low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® via MDI, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Respimat®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Study: NCT00990600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reduced number of pills
Description: Switch to a fixed dose combination one pill/daily HAART
Study: NCT01096472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41003
Description: Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189961
Description: Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189962
Description: Once daily
Study: NCT00862043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: 40 mg t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo t.i.d.
Study: NCT03614663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYN002 - Cannabidiol Transdermal Gel
Description: Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transdermal Gel
Description: Placebo formulated as a clear gel (transdermal delivery)
Study: NCT04039906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removal of needle with using ANDYs
Description: 1. ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~2. Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~   Identify the number of syringes processed by ANDY.~3. After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary.
Study: NCT01532648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide MMX®
Description: Oral tablet taken daily in the morning after breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ASA
Description: Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-ASA
Description: Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g
Study: NCT03311360

Intervention type: DEVICE
Intervention: drug-coated balloon
Description: Orchid and Dahlia DCB

Intervention type: DEVICE
Intervention: bare metal stent
Description: any type of bare metal stent
Study: NCT01750684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC105

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00575016

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Normal saline (Placebo); botulinum toxin Type A (200U)
Description: Placebo injection on Day 1 and botulinum toxin Type A injection 200 U \> Week 12; injection into the detrusor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (50U); botulinum toxin Type A (200U)
Description: botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (100U); botulinum toxin Type A (200U)
Description: botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (200U)
Description: botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
Study: NCT01970410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide
Description: 14 mg oral teriflunomide daily
Study: NCT02568215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by IV infusion; total dose will vary based on participant's weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by IV infusion; total dose will vary based on participant's weight

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VRC01
Description: Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
Study: NCT02148705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NexoBrid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel Vehicle
Study: NCT03085433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfluidic Sperm Sorting
Description: Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: in vitro fertilization
Description: ivf/icsi

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro fertilization
Description: ivf/icsi
Study: NCT01475266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EO9 (Apaziquone)
Description: 4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
Study: NCT02299349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine liposome suspension
Description: bupivacaine liposome suspension periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL
Description: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
Study: NCT00457119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
Study: NCT01319838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: \>12 kg: 160 mg/m2/day, given PO, divided BID \<=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
Study: NCT04418479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period.
Study: NCT03056313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive support of labor
Description: In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: support of labor as usual
Description: In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
Study: NCT01624493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
Study: NCT03039270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: With sonic activation (SMART Device®)
Description: The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM, SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the sonic activation side, immediately after the gel's application, sonic activation(Smart Sonic Device, FGM, SC, Brazil) was performed for 1.5 minutes in total for side (30 seconds per tooth). After the time of 30 seconds in each of the three anterior teeth of the respective side, the gel was removed from teeth with cotton. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (Without sonic activation)
Description: The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM,SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the side allocated for application without sonic activation, gel was kept for 10 minutes, after which it was removed from the teeth. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
Study: NCT01624493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
Study: NCT03039426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: diclofenac 75 mg intramuscular, 2 hours postoperation
Study: NCT03283384

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Letrozole 2.5 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Description: Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).
Study: NCT01624493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
Study: NCT02505087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine followed by Placebo
Description: Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo followed by N-Acetylcysteine
Description: Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
Study: NCT04421300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smile exercise
Description: Launch the smile face recognition APP on smart phone, after user guidance and pretest, a smile exercise will display on the phone, while facing the front camera on the phone, participant will do an exercise emphasizing facial movements, as exaggerated as possible. The exercise last for 8 weeks and 4 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% sodium hyaluronate eye drop
Description: 0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.